DNA repair inhibition: A selective tumour targeting strategy

Trends in Molecular Medicine

Volumn 11, Issue 11, 2005, Pages 503-511

  Madhusudan, Srinivasan ^a   Hickson, Ian D ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 6 O BENZYLGUANINE; 8 HYDROXY 2 METHYL 4(3H) QUINAZOLINONE; AG 14361; AG 14699; ANTINEOPLASTIC AGENT; AZIRIDINE DERIVATIVE; BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CEP 6800; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; E 3330; ETOPOSIDE; FOTEMUSTINE; GPI 15427; IC 87102; IC 87361; IDARUBICIN; IFOSFAMIDE; KU 0055933; LOMUSTINE; MELPHALAN; METHOXYAMINE; MITOMYCIN C; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NITROSOUREA DERIVATIVE; NU 1064; NU 1085; NU 7026; NU 7441; O6 (4 BROMOTHENYL)GUANINE; OK 1035; OXALIPLATIN; STREPTOZOCIN; TEMOZOLOMIDE; THIOTEPA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANAPLASTIC CARCINOMA; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SUSCEPTIBILITY; CLINICAL TRIAL; CYTOTOXICITY; DNA DAMAGE; DNA REPAIR; DNA STRAND; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG POTENCY; EXCISION REPAIR; GENE EXPRESSION; GENE MUTATION; GENETIC DIFFERENCE; GLIOMA; HUMAN; MELANOMA; NONHUMAN; PROTEIN EXPRESSION; REVIEW;

CELL CYCLE PROTEINS; DNA REPAIR; DNA-BINDING PROTEINS; HUMANS; HYDROXYLAMINES; NEOPLASMS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 27844511579     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2005.09.004     Document Type: Review

References (66)

1. A. Sancar Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints Annu. Rev. Biochem. 73 2004 39 85
2. S.L. Gerson MGMT: its role in cancer aetiology and cancer therapeutics Nat. Rev. Cancer 4 2004 296 307
3. C.H. Bassing, and F.W. Alt The cellular response to general and programmed DNA double strand breaks DNA Repair (Amst.) 3 2004 781 796
4. R.M. Costa The eukaryotic nucleotide excision repair pathway Biochimie 85 2003 1083 1099
5. M.J. Schofield, and P. Hsieh DNA mismatch repair: molecular mechanisms and biological function Annu. Rev. Microbiol. 57 2003 579 608
6. M.L. Hefferin, and A.E. Tomkinson Mechanism of DNA double-strand break repair by non-homologous end joining DNA Repair (Amst.) 4 2005 639 648
7. A. Dudas, and M. Chovanec DNA double-strand break repair by homologous recombination Mutat. Res. 566 2004 131 167
8. P. Jagtap, and C. Szabo Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors Nat. Rev. Drug Discov. 4 2005 421 440
9. J.H. Hoeijmakers Genome maintenance mechanisms for preventing cancer Nature 411 2001 366 374
10. A. Shiraishi Increased susceptibility to chemotherapeutic alkylating agents of mice deficient in DNA repair methyltransferase Carcinogenesis 21 2000 1879 1883
11. M.R. Middleton, and G.P. Margison Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway Lancet Oncol. 4 2003 37 44
12. S.M. Chang Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1- nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial Cancer 100 2004 1712 1716
13. A.W. Tolcher Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules Br. J. Cancer 88 2003 1004 1011
14. M.E. Dolan Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents Proc. Natl. Acad. Sci. U. S. A. 87 1990 5368 5372
15. K.Y. Tserng Pharmacokinetics of O6-benzylguanine (NSC637037) and its metabolite, 8-oxo-O6-benzylguanine J. Clin. Pharmacol. 43 2003 881 893
16. M.R. Middleton Effect of O6-(4-bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft model Int. J. Cancer 100 2002 615 617
17. M.R. Middleton O(6)-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts Int. J. Cancer 85 2000 248 252
18. L. Liu, and S.L. Gerson Therapeutic impact of methoxyamine: blocking repair of abasic sites in the base excision repair pathway Curr. Opin. Investig. Drugs 5 2004 623 627
19. T. Izumi Mammalian DNA base excision repair proteins: their interactions and role in repair of oxidative DNA damage Toxicology 193 2003 43 65
20. S. Boiteux, and M. Guillet Abasic sites in DNA: repair and biological consequences in Saccharomyces cerevisiae DNA Repair (Amst.) 3 2004 1 12
21. G. Tell The Intracellular localization of APE1/Ref-1: more than a passive phenomenon? Antioxid. Redox Signal. 7 2005 367 384
22. P. Taverna Methoxyamine potentiates DNA single strand breaks and double strand breaks induced by temozolomide in colon cancer cells Mutat. Res. 485 2001 269 281
23. L. Liu Base excision repair as a therapeutic target in colon cancer Clin. Cancer Res. 8 2002 2985 2991
24. P. Taverna Inhibition of base excision repair potentiates iododeoxyuridine-induced cytotoxicity and radiosensitization Cancer Res. 63 2003 838 846
25. J.L. Parsons APE1 is the major 3′-phosphoglycolate activity in human cell extracts Nucleic Acids Res. 32 2004 3531 3536
26. S. Madhusudan Isolation of a small molecule inhibitor of DNA base excision repair Nucleic Acids Res. 33 2005 4711 4724
27. Meihua Luo, D.C. et al. (2004) Inhibition of the human apurinic/apyrimidinic endonuclease DNA base excision repair enzyme/redox factor (APE1/Ref-1) using small molecule redox and repair inhibitors; therapeutic implications. In American Association for Cancer Research meeting (Abstract No. 3042)
28. H.Y. Hu Identification of small molecule synthetic inhibitors of DNA polymerase beta by NMR chemical shift mapping J. Biol. Chem. 279 2004 39736 39744
29. M. Molinete Overproduction of the poly(ADP-ribose) polymerase DNA-binding domain blocks alkylation-induced DNA repair synthesis in mammalian cells EMBO J. 12 1993 2109 2117
30. J.M. de Murcia Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells Proc. Natl. Acad. Sci. U. S. A. 94 1997 7303 7307
31. Haince, J.F. et al. Targeting poly(ADP-ribosyl)ation: a promising approach in cancer therapy. Trends Mol. Med. (in press)
32. K.J. Bowman Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064 Br. J. Cancer 78 1998 1269 1277
33. E. Willmore A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia Blood 103 2004 4659 4665
34. S.J. Veuger Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1 Cancer Res. 63 2003 6008 6015
35. Griffin, R.J. et al. (2004) Identification of the potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor NU7441 by screening of chromenone libraries. In American Association for Cancer Research (Abstract No. 5362)
36. Shinohara, E. et al. (2004) Radiosensitization by the novel DNA-dependent protein kinase (DNA-PK) inhibitors, IC87102 and IC87361 in animal tumor models. In American Association for Cancer Research (Abstract No. 1353)
37. T. Ortiz Radiosensitizer effect of wortmannin in radioresistant bladder tumoral cell lines Int. J. Oncol. 24 2004 169 175
38. N.G. Oliveira DNA-PK inhibitor wortmannin enhances DNA damage induced by bleomycin in V79 Chinese hamster cells Teratog. Carcinog. Mutagen. 22 2002 343 351
39. M. Stockley Synthesis, crystal structure determination, and biological properties of the DNA-dependent protein kinase (DNA-PK) inhibitor 3-cyano-6-hydrazonomethyl-5-(4-pyridyl)pyrid-[1H]-2-one (OK-1035) Bioorg. Med. Chem. Lett. 11 2001 2837 2841
40. R. Okayasu Radiosensitization of normal human cells by LY294002: cell killing and the rejoining of DNA and interphase chromosome breaks J. Radiat. Res. (Tokyo) 44 2003 329 333
41. A.K. Gupta Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002 Int. J. Radiat. Oncol. Biol. Phys. 56 2003 846 853
42. I. Hickson Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM Cancer Res. 64 2004 9152 9159
43. C. Couture, and T.Y. Chow Purification and characterization of a mammalian endo-exonuclease Nucleic Acids Res. 20 1992 4355 4361
44. T.Y. Chow The DNA double-stranded break repair protein endo-exonuclease as a therapeutic target for cancer Mol. Cancer Ther. 3 2004 911 919
45. Z.H. Siddik Cisplatin: mode of cytotoxic action and molecular basis of resistance Oncogene 22 2003 7265 7279
46. M. Selvakumaran Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines Cancer Res. 63 2003 1311 1316
47. M. Ferrer Chemosensitizing tumor cells by targeting the Fanconi anemia pathway with an adenovirus overexpressing dominant-negative FANCA Cancer Gene Ther. 11 2004 539 546
48. J.A. Plumb Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter Cancer Res. 60 2000 6039 6044
49. J.A. Plumb Epigenetic approaches to cancer therapy Biochem. Soc. Trans. 32 2004 1095 1097
50. S.J. Collis Enhanced radiation and chemotherapy-mediated cell killing of human cancer cells by small inhibitory RNA silencing of DNA repair factors Cancer Res. 63 2003 1550 1554
51. C.H. Kim A targeted inhibition of DNA-dependent protein kinase sensitizes breast cancer cells following ionizing radiation J. Pharmacol. Exp. Ther. 303 2002 753 759
52. S.L. Matheson Design of a chimeric 3-methyl-1,2,3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: a novel tumor targeting strategy J. Pharmacol. Exp. Ther. 296 2001 832 840
53. S.L. Matheson Differential responses of EGFR-/AGT-expressing cells to the "combi-triazene' SMA41 Cancer Chemother. Pharmacol. 51 2003 11 20
54. F. Brahimi Inhibition of epidermal growth factor receptor-mediated signaling by 'Combi-triazene' BJ2000, a new probe for Combi-Targeting postulates J. Pharmacol. Exp. Ther. 303 2002 238 246
55. H.E. Bryant Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase Nature 434 2005 913 917
56. H. Farmer Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 434 2005 917 921
57. Gallmeier, E. and Kern, S.E. (2005) Absence of specific cell killing of the BRCA2-deficient human cancer cell line CAPAN1 by poly(ADP-ribose)polymerase inhibition. Cancer Biol Ther. 4, http:www.landesbiosciences.com/journals/cbt/ abstract.php?id=1909
58. W.L. Kraus, and J.T. Lis PARP goes transcription Cell 113 2003 677 683
59. Y. Harima Expression of Ku80 in cervical cancer correlates with response to radiotherapy and survival Am. J. Clin. Oncol. 26 2003 e80 e85
60. A.R. Snyder, and W.F. Morgan Gene expression profiling after irradiation: clues to understanding acute and persistent responses? Cancer Metastasis Rev. 23 2004 259 268
61. E.L. Goode Polymorphisms in DNA repair genes and associations with cancer risk Cancer Epidemiol. Biomarkers Prev. 11 2002 1513 1530
62. S. Gurubhagavatula XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy J. Clin. Oncol. 22 2004 2594 2601
63. C. Camps Assessment of nucleotide excision repair XPD polymorphisms in the peripheral blood of gemcitabine/cisplatin-treated advanced non-small-cell lung cancer patients Clin. Lung Cancer 4 2003 237 241
64. W. Zhou Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy Clin. Cancer Res. 10 2004 4939 4943
65. A.D. Roses Pharmacogenetics and the practice of medicine Nature 405 2000 857 865
66. V.D. Schmith Pharmacogenetics and disease genetics of complex diseases Cell. Mol. Life Sci. 60 2003 1636 1646